Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Mikrogen Ink Lyme Disease Diagnostic Deal

NEW YORK (GenomeWeb) – Protagen and Mikrogen announced today that they have signed a deal to co-develop a new diagnostic assay to differentiate previously infected, seropositive Lyme disease patients from newly infected individuals with active disease.

The companies, which have long been collaborators, said that they have already identified Lyme disease biomarker panels using Protagen's SeroTag technology, which uses Luminex-based screens of patient sera against large sets of proteins to identify autoantibody signatures that are prognostic or diagnostic for various conditions. Under the newest arrangement, Mikrogen will be responsible for the development and commercialization of a final diagnostic assay.

Under the newest arrangement, Mikrogen will be responsible for the diagnostic assay's development and commercialization. Additional terms were not disclosed.

"The new biomarkers have the potential to significantly improve current Lyme disease diagnostics, as they offer a completely novel approach to the identification of patients actively suffering from the disease," Protagen CEO Stefan Müllner said in a statement. "We are pleased to have leveraged our technology and development capabilities in a new therapeutic area, with a strong and experienced partner in this field. We look forward to utilizing this approach for other infectious diseases, too." 

In late 2013, Protagen signed a deal with Pfizer to use the SeroTag technology to identify biomarkers for an undisclosed autoimmune disease therapy under development by the pharma giant.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.